Wave Life Sciences Ltd. expects to pitch using caudate atrophy as a surrogate endpoint to support accelerated approval of its WVE-003 in Huntington's disease to regulators by the end of the year.
Key Takeaways
-
Wave announced positive efficacy data for WVE-003 in Huntington’s disease, with statistically significant reductions in mutant huntingtin protein and promising imaging biomarker data.
The Cambridge, MA-based biotech's case may be helped by positive Phase Ib/IIa efficacy data, although potential safety concerns about neurofilament...